ClinicalTrials.gg
RecruitingNCT06499233Updated Oct 1, 2024

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

A Phase 4 interventional study of Trimethoprim/Sulfamethoxazole in Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease and Autoimmune Diseases, sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Tongji Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Pneumonia, Pneumocystis with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Pneumonia, Pneumocystis · China.

Started
2024
the only one that year
Phase 4
3 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Tongji Hospital

Among the 11 studies in Pneumonia, Pneumocystis with a site in China, this one is the only one that started in 2024, is one of 3 in phase 4, and was the 11th registered.

Pneumonia, Pneumocystis

108 studies on the registry are indexed under Pneumonia, Pneumocystis; 16 are open to participants now.

Browse Pneumonia, Pneumocystis studies →

Open to participants now

1 of the 11 studies in Pneumonia, Pneumocystis with a site in China is open now.

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 9 Pneumonia, Pneumocystis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pneumonia, Pneumocystis with a site in China, or all of them as a file.
02

Study summary

This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.

03

Conditions studied

  • Pneumonia, Pneumocystis
  • Autoimmune Inflammatory Rheumatic Disease
  • Autoimmune Diseases
  • Connective Tissue Disease
  • Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient was diagnosed with AIIRD according to the International Classification of Diseases and had received or therapy;
  2. The patient had not received standard PJP treatment before enrollment, including the treatment drug TMP/SMZ, or other second-line treatment drugs (including Pentamidine, Atorvastatin, Caspofungin, etc.);
  3. The patient was at least 18 years old at the time of enrollment;

Exclusion criteria

Exclusion Criteria:

  1. Serious health problems or diseases, including (but not limited to) the following: severe liver damage (, AST elevated above normal value by more than 5 times), severe renal insufficiency ( \< 30mL/min or Scr > 445umol/L), severe myelosuppression ( \< 65g/L, \< 25×10\^9/L or neutrophils \< 0.5×10\^9/L);
  2. Screening test indicates infection with (HIV), history of lymphomatous hyperplasia of the lymphatic tissue or any malignant tumor of any organ system within the past 5 years, or history of organ transplantation;
  3. Participants with a history of allergy to sulfonamide drugs, megaloblastic anemia due to folate deficiency;
  4. Pregnant and lactating women;
  5. Any medical or psychological condition that the investigator believes would interfere with the participant's ability to comply with the protocol or complete the study;
  6. Patients who refuse to comply with the requirements of this study and complete the study;
  7. Any other situation that the investigator considers unsuitable for participation in the study (for reasons including but not limited to management reasons).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    TMP/SMX (with PJP high risk)

    AIIRD patients who have PJP high risk and receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment; Drug intervention: Patients receive Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis.

    Drug: Trimethoprim/Sulfamethoxazole

  • No intervention
    no TMP/SMX (with PJP high risk)

    AIIRD patients who have PJP high risk and do not receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment.

  • Experimental
    TMP/SMX (with PJP low-risk)

    AIIRD patients who have PJP low risk and receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment; Drug intervention: Patients receive Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis.

    Drug: Trimethoprim/Sulfamethoxazole

  • No intervention
    no TMP/SMX (with PJP low-risk)

    AIIRD patients who have PJP low risk and do not receive prophylactic Trimethoprim/ Sulfamethoxazole (TMP/SMZ) treatment.

Interventions

  • DrugTrimethoprim/Sulfamethoxazole

    Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).

    Also known as: TMP/SMX

06

What researchers measure

Primary outcomes

  1. Number of participants with PJP infection

    Defined as documentation/diagnosis of Pneumocystis from a properly obtained specimen (induced sputum, bronchoalveolar lavage, or biopsy) in a patient with clinical manifestations compatible with PJP.

    Time frame: 6 months, 12 months

Secondary outcomes

  1. TMP/SMZ related adverse drug reactions

    Symptoms and signs that may be related to adverse drug reactions during treatment (such as nausea, vomiting, anorexia, jaundice, rashes and hives, and shock); incidence, duration and severity of adverse events

    Time frame: 6 months, 12 months

  2. PJP-related mortality

    PJP-related mortality at the end of month 6.

    Time frame: 6 months, 12 months

  3. All cause mortality

    All cause mortality

    Time frame: 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2024
First posted
Jul 12, 2024
StartActual
Jul 20, 2024
Primary completionEst.
Jul 20, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06499233
Lead sponsor
Tongji Hospital
Responsible party
Lingli Dong (Professor, Tongji Hospital) — Principal investigator
First posted
Jul 12, 2024
Start date
Jul 20, 2024
Primary completion
Jul 20, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 1, 2024

Study contacts

Lingli Dong
Contact
tjhdongll@163.com
02783665519
Shaozhe Cai
Contact
540361903@qq.com
02783665518
Lingli Dong
principal investigator · Tongji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion